Soleno Therapeutics (SLNO) Short-term Investments (2024 - 2026)

Soleno Therapeutics (SLNO) has 3 years of Short-term Investments data on file, last reported at $122.6 million in Q1 2026.

• Short-term Investments for Q1 2026 came in at $122.6 million, down 41.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $122.6 million (down 41.24% YoY), and the FY2025 annual result was $235.4 million, up 15.65% from the prior year.
• Short-term Investments fell to $122.6 million in Q1 2026 per SLNO's latest filing, from $235.4 million in the prior quarter.
• Over five years, Short-term Investments peaked at $252.3 million in Q3 2025 and troughed at $106.8 million in Q1 2024.
• A 3-year average of $195.2 million and a median of $208.6 million in 2025 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2025 and 2026: Short-term Investments jumped 95.32% in 2025, then slumped 41.24% in 2026.
• A 3-year view of Short-term Investments shows it stood at $203.5 million in 2024, then grew by 15.65% to $235.4 million in 2025, then sank by 47.92% to $122.6 million in 2026.
• Business Quant data shows SLNO's Short-term Investments at $122.6 million in Q1 2026, $235.4 million in Q4 2025, and $252.3 million in Q3 2025.